Geovax Labs Inc SEC Filings

GOVXW NASDAQ

Welcome to our dedicated page for Geovax Labs SEC filings (Ticker: GOVXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

GeoVax Labs’ disclosures are more than numbers—they map the scientific road from bench to bedside. Yet parsing a biotech 10-K crowded with clinical-trial risk factors, patent claims, and warrant details can stall your research. Stock Titan answers that pain point by turning every GeoVax Labs SEC filing into an approachable brief the moment it hits EDGAR.

Want the GeoVax Labs insider trading Form 4 transactions without scrolling hundreds of lines? Our AI highlights real-time Form 4 insider transactions so you can spot warrant exercises and executive stock moves instantly. Need the GeoVax Labs quarterly earnings report 10-Q filing for cash-runway analysis? We surface burn rate, trial costs, and partnership revenue in plain language. Curious about pipeline progress hidden in an 8-K? You’ll find “GeoVax Labs 8-K material events explained” beside the original document.

Here’s how investors use the page:

Track GeoVax Labs Form 4 insider transactions real-time before material announcements.
Compare R&D spend across quarters with our GeoVax Labs earnings report filing analysis.
Understand dual-antigen vaccine milestones via GeoVax Labs annual report 10-K simplified summaries.
Review GeoVax Labs proxy statement executive compensation to gauge management incentives.

Every document—10-K, 10-Q, 8-K, S-1, or DEF 14A—arrives with AI-powered summaries, key-term search, and expert context. So whether you’re understanding GeoVax Labs SEC documents with AI for diligence or monitoring GeoVax Labs executive stock transactions Form 4, Stock Titan lets you move from raw data to decision in minutes.

06/26/2025 05:29 PM

Filing

[S-1/A] GeoVax Labs, Inc. Warrants Amends IPO Registration Statement

Rhea-AI Summary

The Amendment No. 1 to Form S-1 filed by GeoVax Labs, Inc. (symbol: GOVXW) registers a best-efforts public offering of up to 8,333,334 Common Units at an assumed price of $0.90 per unit. Each Common Unit contains one share of common stock and two five-year Common Warrants.

For investors preferring to avoid exceeding 4.99% (or optionally 9.99%) ownership thresholds, the filing also offers up to 8,333,334 Pre-Funded Units, each comprised of one Pre-Funded Warrant plus two Common Warrants. In total, the statement covers up to 25,000,002 shares of common stock issuable upon warrant exercise.

The company is a non-accelerated filer and qualifies as a smaller reporting company. No underwriter is obligated to purchase the securities; sales will commence “as soon as practicable” after effectiveness. The document is preliminary and subject to completion.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Geovax Labs (GOVXW)?

The current stock price of Geovax Labs (GOVXW) is $0.025001 as of June 27, 2025.

What is the primary focus of GeoVax Labs Inc?

GeoVax Labs Inc is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and solid tumor cancers using its proprietary MVA-VLP platform.

What technology underpins GeoVax Labs' vaccine development?

The company uses a modified vaccinia ankara virus-like particle (MVA-VLP) platform, which induces both humoral and cellular immune responses by producing non-infectious viral particles in vivo.

Which therapeutic areas does GeoVax concentrate on?

GeoVax explorers multiple therapeutic areas including infectious diseases such as COVID-19, Monkeypox, and hemorrhagic fever viruses, as well as oncology through gene-directed therapies for solid tumors like head and neck cancers.

How does GeoVax differentiate its COVID-19 vaccine candidate?

GeoVax’s COVID-19 vaccine candidate employs a dual-antigen strategy by encoding both the spike and nucleocapsid proteins, a design intended to elicit a broader and more durable immune response.

What is the significance of the company’s intellectual property portfolio?

The robust IP portfolio, including numerous patents on its MVA-VLP platform and related technologies, not only protects GeoVax’s innovations but also positions the company advantageously in a competitive biotech landscape.

How does GeoVax approach its clinical trial strategy?

GeoVax conducts multiple Phase 2 clinical trials across different patient populations, focusing on both immunocompromised and healthy individuals, to evaluate the efficacy and safety of its cutting-edge vaccines and immunotherapies.

What makes GeoVax Labs a notable player in biotechnology?

The company’s integration of advanced viral vector technology with a strategic dual-antigen and gene-directed approach refines its ability to develop vaccines and therapies for complex medical challenges, demonstrating deep industry expertise.